sisomicin has been researched along with Bacterial Infections, Gram-Negative in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Avison, MB; Okazaki, A | 1 |
| Bassetti, M; Battaglini, D; Giacobbe, DR; Pelosi, P; Vena, A | 1 |
| Garcia, JA; Liang, SY; Long, B; Matlock, A; Moussavi, K | 1 |
| Chahine, EB; Cho, JC; Piccicacco, N; Shaeer, KM; Zmarlicka, MT | 1 |
| Alharbi, A; Alshehri, S; Eljaaly, K; Ortwine, JK; Pogue, JM | 1 |
| Falagas, ME; Papazoglou, AA; Rafailidis, PI; Tansarli, GS | 1 |
| Armstrong, ES; Miller, GH | 1 |
6 review(s) available for sisomicin and Bacterial Infections, Gram-Negative
| Article | Year |
|---|---|
The role of new antimicrobials for Gram-negative infections in daily clinical practice.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactams; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Imipenem; Microbial Sensitivity Tests; Polymyxins; Sisomicin; Tazobactam; Tetracyclines | 2020 |
Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Design; Drug Resistance, Multiple; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Humans; Meropenem; Sisomicin; Tazobactam; Tetracyclines | 2021 |
Plazomicin: A Next-Generation Aminoglycoside.
Topics: Adult; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Sisomicin; Urinary Tract Infections | 2019 |
Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Clinical Trials as Topic; Colistin; Dose-Response Relationship, Drug; Drug Approval; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem; Randomized Controlled Trials as Topic; Sisomicin; United States; United States Food and Drug Administration; Urinary Tract Infections | 2019 |
Antimicrobial activity and clinical effectiveness of sisomicin: an evaluation of the literature (1995-2011).
Topics: Anti-Bacterial Agents; Cohort Studies; Databases, Bibliographic; Enterococcus; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Sisomicin; Staphylococcus; Stenotrophomonas maltophilia; Treatment Outcome | 2013 |
Combating evolution with intelligent design: the neoglycoside ACHN-490.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Microbial Sensitivity Tests; Molecular Structure; Sisomicin | 2010 |
1 other study(ies) available for sisomicin and Bacterial Infections, Gram-Negative
| Article | Year |
|---|---|
Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Butirosin Sulfate; Drug Resistance, Multiple, Bacterial; Escherichia coli; Gram-Negative Bacterial Infections; Humans; Kanamycin; Kanamycin Kinase; Microbial Sensitivity Tests; Mutation; Neomycin; Stenotrophomonas maltophilia | 2007 |